IPSC-Derived NK Cells Clinical Trial Pipeline Analysis: 12+ Key Companies Shaping the Future of IPSC-Derived NK Cells Therapeutics | DelveInsight

DelveInsight's IPSC-Derived NK Cells Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline IPSC-Derived NK Cells therapies in various stages of clinical development. The report provides insights into 12+ companies and 15+ pipeline drugs in the IPSC-Derived NK Cells pipeline landscape, covering clinical and nonclinical stage products, therapeutic assessments, and inactive pipeline products.

Key takeaways from the IPSC-Derived NK Cells Clinical Trial Landscape Report

• DelveInsight's IPSC-Derived NK Cells pipeline report depicts a developing space with 12+ companies working to develop 15+ pipeline therapies for IPSC-Derived NK Cells.
• Key IPSC-Derived NK Cells companies such as Century Therapeutics, Inc., Fate Therapeutics, Cartherics Pty Ltd, Nuwacell Biotechnologies Co., Ltd, HebeCell, BrightPath Biotherapeutics, and Qihan Biotech.
• Promising IPSC-Derived NK Cells pipeline therapies in various stages of development include CNTY-101, FT522, CTH-401, NCR300, HC101a, BP 2201, QN-139b, and others.

Request a sample and discover the recent advances in IPSC-Derived NK Cells therapies https://www.delveinsight.com/sample-request/ipsc-derived-nk-cells-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What are IPSC-Derived NK Cells?

iPSC-derived NK cells are natural killer immune cells generated from induced pluripotent stem cells (iPSCs), providing a scalable and standardized platform for next-generation cancer immunotherapy. They are produced through a controlled differentiation process in which iPSCs first develop into CD34+ hematopoietic progenitor cells and then mature into functional NK cells under cytokine stimulation, particularly Interleukin-15.
During maturation, the cells express key cytotoxic molecules such as granzyme B (GZMB) and perforin (PRF1), enabling them to recognize and eliminate malignant cells, especially those lacking Human Leukocyte Antigen class I expression. Compared with donor-derived NK cells, iPSC-derived NK cells minimize donor variability and support large-scale "off-the-shelf" manufacturing, while their stable genetic background allows precise engineering, including integration of Chimeric Antigen Receptor (CAR) constructs to enhance tumor targeting.
As a therapeutic platform, iPSC-derived NK cells are being explored for both hematologic and solid tumors. Their scalable production enables standardized cell therapies for diseases such as Leukemia and Lymphoma, as well as other treatment-resistant malignancies. These engineered immune cells are also being investigated in Lung Cancer, Ovarian Cancer, Melanoma, Myeloid Leukemia, and Hepatocellular Carcinoma.

Emerging IPSC-Derived NK Cells Drug Profiles

CNTY-101: Century Therapeutics, Inc.
CNTY-101 is an investigational, off-the-shelf cell therapy developed by Century Therapeutics and derived from induced pluripotent stem cells (iPSCs). It is engineered into CD19-targeted chimeric antigen receptor natural killer (CAR-NK) cells and is designed to selectively deplete CD19-positive B cells. CNTY-101 incorporates genetic modifications intended to enhance persistence, functionality, and resistance to immune rejection. Currently, CNTY-101 is being evaluated in a Phase I/II trial in patients with B-cell mediated autoimmune diseases.

FT522: Fate Therapeutics
FT522 is an investigational, off-the-shelf CAR-NK cell therapy derived from induced pluripotent stem cells (iPSCs) and developed by Fate Therapeutics. The therapy is engineered with a Chimeric Antigen Receptor (CAR) targeting CD19 expressed on malignant B cells. It also incorporates a proprietary Alloimmune Defense Receptor (ADR) designed to improve persistence by eliminating activated alloreactive immune cells that could otherwise reject the therapy. Currently, FT522 is being evaluated in Phase I clinical trials for the treatment of Relapsed/Refractory B-Cell Lymphoma.

CTH-401: Cartherics Pty Ltd
CTH-401 is an emerging iPSC-derived NK cell therapy included in DelveInsight's IPSC-Derived NK Cells pipeline landscape. The therapy is being investigated as an engineered cellular immunotherapy and is included among the preclinical and discovery-stage products covered in the report.

Learn more about the novel and emerging IPSC-Derived NK Cells pipeline therapies https://www.delveinsight.com/sample-request/ipsc-derived-nk-cells-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Scope of the IPSC-Derived NK Cells Pipeline Report

• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Phase III, Phase II, Phase I, Preclinical, Discovery
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
• Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy
• Key IPSC-Derived NK Cells Companies: Century Therapeutics, Inc., Fate Therapeutics, Cartherics Pty Ltd, Nuwacell Biotechnologies Co., Ltd, HebeCell, BrightPath Biotherapeutics, Qihan Biotech
• Key IPSC-Derived NK Cells Pipeline Therapies: CNTY-101, FT522, CTH-401, NCR300, HC101a, BP 2201, QN-139b.

Dive deep into rich insights for emerging IPSC-Derived NK Cells therapies, visit https://www.delveinsight.com/sample-request/ipsc-derived-nk-cells-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents

1. IPSC-Derived NK Cells Pipeline Report Introduction
2. IPSC-Derived NK Cells Pipeline Report Executive Summary
3. IPSC-Derived NK Cells: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. IPSC-Derived NK Cells Pipeline Therapeutics
6. IPSC-Derived NK Cells Pipeline: Late Stage Products (Phase III)
7. IPSC-Derived NK Cells Pipeline: Mid Stage Products (Phase II)
8. IPSC-Derived NK Cells Pipeline: Early Stage Products (Phase I)
9. IPSC-Derived NK Cells Pipeline: Preclinical and Discovery Stage Products
10. IPSC-Derived NK Cells Pipeline Therapeutics Assessment
11. Inactive Products in the IPSC-Derived NK Cells Pipeline
12. Key Companies
13. Key Products in the IPSC-Derived NK Cells Pipeline
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

For further information on the IPSC-Derived NK Cells pipeline therapeutics, reach out https://www.delveinsight.com/sample-request/ipsc-derived-nk-cells-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +1-469-945-7679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, DelveInsight offers customized research solutions and insights to clients across the globe.

This release was published on openPR.